Our Board of Directors

Dr. Andrew Cavey:

CEO ITM Group

Dr. Andrew Cavey joined ITM as Chief Executive Officer on September 1, 2024 to lead the company, already a bedrock of the radiopharmaceutical industry, as it grows and furthers its leadership in Radiopharmaceutical Therapy innovation.

Andrew is a physician and an experienced healthcare executive, with expertise and a successful track record in radiopharmaceutical drug development and commercialization across leading global biopharmaceutical organizations. He will help guide ITM’s continued progress in its pipeline and radioisotope manufacturing capacities.

Before joining ITM, Andrew was SVP, Head of Global Program Leaders, Hematology, Oncology, Cell Therapy at Bristol Myers Squibb. Over the course of his career, he has also held a number of corporate strategy, commercial and drug development leadership roles at Novartis culminating in his role as Global Program Head, Prostate Cancer, in which he co-led the company’s Radiopharmaceutical Therapy strategy and led teams overseeing the clinical development and regulatory approvals of radiopharmaceuticals in the US and Europe. In his early career, he practiced medicine as a physician in the UK’s NHS, and worked as a humanitarian aid worker for various non-governmental organizations in sub-Saharan Africa and South Asia.

Andrew holds physiological sciences and medical degrees from Oxford University, and a Master’s in Public Health from Harvard University. He gained membership to the UK Royal College of Physicians and currently serves as a Board Trustee for Parkinson's UK. He is married and has three children.

Jack Craig Jr.:

President and CEO, CNL

Mr. Craig is a seasoned nuclear industry veteran with extensive knowledge of our operations as the former Chair of the Board of Directors for CNEA. Jack has over 30 years of experience gained through high-level technical, management and executive leadership positions both at the U.S. Department of Energy (DOE) Headquarters and DOE field offices, and most recently served as the Chief Operating Officer for AtkinsRéalis US Nuclear where he oversaw the operation and growth of the company’s U.S. and global nuclear business.

Dr. Mark Harfensteller:

COO ITM Group

Dr. Mark Harfensteller joined ITM as Head of Production and R&D in 2008. In 2016, he became Managing Director of ITM Medical Isotopes. Under Mark’s leadership, the company established an industrial and GMP compliant production, meeting the demand of the rapidly expanding radioisotope market. Prior to his work at ITM, Mark successfully completed a project at the Institute of Machine Tools and Industrial Management (TUM), focusing on the development and production of alpha-emitter, 225Ac, via the irradiation of 226Ra in a cyclotron. The project has been nominated for the “Deutscher Zukunftspreis”. Mark holds a PhD in Mechanical Engineering from the Technical University of Munich (TUM) (Germany).

Stephen Bushby:

Vice-President Science & Technology, CNL

Steve is a senior nuclear executive with a long and accomplished career, previously working as the Chief Nuclear Officer at AIC Global Holdings, where he identified and assessed investment opportunities in small modular reactor (SMR), clean energy and targeted radio therapy technologies. Steve has spent much of his career working at AECL in progressive leadership roles, including serving as the Vice-President of Science, Technology and Commercial Oversight, where he helped define and oversee CNL’s research program, operations, and commercial activities.

Dr. Klaus Maleck:

CFO ITM Group

Dr. Klaus Maleck joined ITM as Chief Financial Officer in June 2021. He has over 25 years of experience as a Biopharmaceutical Industry Executive. Prior to joining ITM, he served as CEO of TETEC AG, a fully integrated regenerative medicine developer and manufacturer within the Aesculap/B Braun group, which grew under Klaus from 30 employees to one of the largest manufacturers in the field. This followed roles as CFO and CBO at EvotecAG, where he drove key corporate development events, including the Nasdaq listing of the company. Earlier in his career, Klaus was Co-Founder and CFO of BioGeneriXAG, the Biosimilarsbusiness of Ratiopharm, and a senior consultant to the life science industry with McKinsey & Co. He began his professional career as a Research Scientist at the Novartis Biotechnology and Genomics Center in NC (USA).

Klaus holds an MBA degree, as well as a master's degree in Biotechnology from the ESBS in Strasbourg (France), and a PhD in Biochemistry from the Max Planck Institute in Cologne (Germany).

Grant Gardiner:

Executive Vice President Strategy and Business Development, Atomic Energy of Canada Limited

As Executive Vice-President Strategy and Business Development, Grant provides strategic leadership for AECL which includes establishing and implementing strategic plans as well as pursuing and integrating strategic business initiatives. These include leading the implementation of AECL’s corporate strategy, the exploitation and oversight of AECL’s CANDU reactor and other intellectual property as well as AECL’s ESG efforts. Grant also works closely with AECL’s President & CEO to assist with the overall management of the organization, including responsibility for AECL’s legal function under the leadership of the General Counsel & Corporate Secretary.

Between 2015 and 2022, Grant was Vice-President, General Counsel & Corporate Secretary for AECL, representing the organization in all matters of law, legal policy and contract interpretation as well as being a member of the Executive team. Grant was admitted to the Ontario Bar in 1993 and has extensive experience leading organizations and their Boards of Directors through complex legal, governance and compliance landscapes, having served at the general counsel and corporate secretary level for more than 20 years.

He holds a Bachelor of Business Administration from the University of Prince Edward Island, an L.L.B. from Osgoode Hall Law School and an ICD.D designation from the Institute of Corporate Directors.

This website uses cookies